Candida bracarensis: Evaluation of Virulence Factors and its Tolerance to Amphotericin B and Fluconazole
- PMID: 26179982
- DOI: 10.1007/s11046-015-9925-y
Candida bracarensis: Evaluation of Virulence Factors and its Tolerance to Amphotericin B and Fluconazole
Abstract
Candida bracarensis is an uncommon Candida species found during an epidemiological study of candidiasis performed in Braga, Portugal. Initially, it was identified as C. glabrata, but recently detailed analyses pointed out their differences. So, little information is still available about C. bracarensis virulence factors and antifungal susceptibilities. Therefore, the main goal of this work is to evaluate the ability of C. bracarensis to form biofilms, to produce hydrolytic enzymes (proteases, phospholipases and hemolysins), as well as its susceptibility to amphotericin B and fluconazole. It was shown, for the first time, that all C. bracarensis strains were able to form biofilms and display proteinase and hemolytic activities. Moreover, although planktonic cells presented antifungal susceptibility, amphotericin B and fluconazole were unable to inhibit biofilm formation and eradicate pre-formed biofilms. Due to the propensity of C. bracarensis to display antifungal resistance and virulence attributes, the control of these emerging pathogens is recommended.
Keywords: Amphotericin B; Antifungal resistance; Candida bracarensis; Fluconazole; Virulence factors.
Similar articles
-
[Biofilm production and antifungal susceptibility patterns of Candida species].Mikrobiyol Bul. 2004 Jan-Apr;38(1-2):91-8. Mikrobiyol Bul. 2004. PMID: 15293907 Turkish.
-
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation.Antimicrob Agents Chemother. 2017 Apr 24;61(5):e02396-16. doi: 10.1128/AAC.02396-16. Print 2017 May. Antimicrob Agents Chemother. 2017. PMID: 28223375 Free PMC article.
-
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.BMC Infect Dis. 2005 Nov 3;5:99. doi: 10.1186/1471-2334-5-99. BMC Infect Dis. 2005. PMID: 16266438 Free PMC article.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Old and new pathogenic Nakaseomyces species: epidemiology, biology, identification, pathogenicity and antifungal resistance.FEMS Yeast Res. 2016 Mar;16(2):fov114. doi: 10.1093/femsyr/fov114. Epub 2015 Dec 20. FEMS Yeast Res. 2016. PMID: 26691882 Review.
Cited by
-
Caenorhabditis elegans as a Model System To Assess Candida glabrata, Candida nivariensis, and Candida bracarensis Virulence and Antifungal Efficacy.Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00824-20. doi: 10.1128/AAC.00824-20. Print 2020 Sep 21. Antimicrob Agents Chemother. 2020. PMID: 32718968 Free PMC article.
-
The birth of a deadly yeast: tracing the evolutionary emergence of virulence traits in Candida glabrata.FEMS Yeast Res. 2016 Mar;16(2):fov110. doi: 10.1093/femsyr/fov110. Epub 2015 Dec 17. FEMS Yeast Res. 2016. PMID: 26684722 Free PMC article. Review.
-
Candida glabrata Antifungal Resistance and Virulence Factors, a Perfect Pathogenic Combination.Pharmaceutics. 2021 Sep 22;13(10):1529. doi: 10.3390/pharmaceutics13101529. Pharmaceutics. 2021. PMID: 34683822 Free PMC article. Review.
-
How much do we know about hemolytic capability of pathogenic Candida species?Folia Microbiol (Praha). 2018 Jul;63(4):405-412. doi: 10.1007/s12223-018-0584-5. Epub 2018 Jan 15. Folia Microbiol (Praha). 2018. PMID: 29335820 Review.
-
Chromosome level assemblies of Nakaseomyces (Candida) bracarensis uncover two distinct clades and define its adhesin repertoire.BMC Genomics. 2024 Nov 7;25(1):1053. doi: 10.1186/s12864-024-10979-8. BMC Genomics. 2024. PMID: 39511470 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources